Finance

Lists
Q2 2027 earnings • released • Revenue beat +१.०६%
See results
STAR:NSE
Strides Pharma Science Ltd
₹ १,०२५.००
-१.१५%
(-११.९०) 1D
नोभेम्बर ३, १५:३०:०० GMT+५:३०  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for STAR...
Open
₹ १,०४०.००
High
₹ १,०५५.००
Low
₹ १,०१०.४०
Mkt. cap
९४.४८ अरब
Avg. vol.
३.४३ लाख
Volume
४.९६ लाख
Dividend
०.४९%
Quarterly dividend
₹ १.२५
Ex-dividend date
२०२६ जुलाई ३१
P/E ratio
१५.४०
52-wk high
₹ १,२६०.९०
52-wk low
₹ ७६८.६५
EPS
₹ ६६.५५
Shares outstanding
८.९६ करोड
No. of employees
४ हजार
Open
₹ १,०४०.००
High
₹ १,०५५.००
Low
₹ १,०१०.४०
Mkt. cap
९४.४८ अरब
Avg. vol.
३.४३ लाख
Volume
४.९६ लाख
Dividend
०.४९%
Quarterly dividend
₹ १.२५
Ex-dividend date
२०२६ जुलाई ३१
P/E ratio
१५.४०
52-wk high
₹ १,२६०.९०
52-wk low
₹ ७६८.६५
EPS
₹ ६६.५५
Shares outstanding
८.९६ करोड
No. of employees
४ हजार
News stories
From web sources and news partners
TradingView
TradingView
·
२ दिन पहिले
Strides Pharma Q2 Revenue Rises 17%, Ex-US Sales Surpass US
Profile
Strides Pharma Science Limited is an Indian pharmaceutical company, headquartered at Bangalore. The company manufactures pharmaceutical products, over-the-counter drugs and nutraceuticals. Products include softgel capsules, hard-gel capsules, tablets and dry and wet injectables. The company has 15 manufacturing sites in six countries and marketing presence in 50 countries. The company partners with generic companies to supply retail and hospital generics in injectable products and softgels. The company's stock trades on the Bombay Stock Exchange and on the National Stock Exchange of India. Strides Arcolab changed name to Strides Shasun Ltd after an amalgamation of Shasun Pharmaceuticals with Strides Arcolab. In September 2014, the Board of Directors of both the companies had approved a scheme of amalgamation between the two companies. Arun Kumar is the founder and chairman, and has been on the board as managing director since its inception. Wikipedia
About Strides Pharma Science Ltd
CEO-
Employees३.५४ हजार
Founded१९९०
Headquartersबेङ्गलोर, कर्नाटक, भारत
Sector-
Last report
२०२६ अक्टोबर ३०
Fiscal period
Q2 2027
- / -
Revenue / Est. (INR)
१४.३० अरब / १४.१५ अरब
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
११.९५ अरब
१३.२३ अरब
१२.६५ अरब
१४.३० अरब
Cost of goods sold
४.६३ अरब
७.१९ अरब
४.९५ अरब
६.२९ अरब
Cost of revenue
४.६३ अरब
७.१९ अरब
४.९५ अरब
६.२९ अरब
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
२.३० अरब
३.४५ अरब
२.४३ अरब
२.३८ अरब
Operating expense
५.४६ अरब
४.९१ अरब
५.९७ अरब
६.०७ अरब
Total operating expenses
१०.०९ अरब
१२.१० अरब
१०.९२ अरब
१२.३६ अरब
Operating income
१.८५ अरब
१.१३ अरब
१.७३ अरब
१.९४ अरब
Other non operating income
१.०७ अरब
-१.६६ अरब
४.८९ करोड
४.०८ करोड
EBT including unusual items
२.४५ अरब
१.४८ अरब
२.०० अरब
१.५० अरब
EBT excluding unusual items
२.४९ अरब
५०.२१ करोड
१.३६ अरब
१.५२ अरब
Income tax expense
३७.३५ करोड
१८.७७ करोड
३४.१२ करोड
१६.३२ करोड
Effective tax rate
१५.२२%
१२.६८%
१७.०९%
१०.८५%
Other operating expenses
२.६६ अरब
९२.८५ करोड
२.९७ अरब
३.११ अरब
Net income
२.०२ अरब
१.२७ अरब
१.५७ अरब
१.३१ अरब
Net profit margin
१६.९२%
९.५९%
१२.४०%
९.१५%
Earnings per share
-
-
-
-
Interest and investment income
-
४०.४८ करोड
-
-
Interest expense
-४३.३८ करोड
-१३.०८ करोड
-४०.५६ करोड
-४६.५४ करोड
Net interest expenses
-४३.३८ करोड
२७.४० करोड
-४०.५६ करोड
-४६.५४ करोड
Depreciation and amortization charges
५०.६२ करोड
५३.२५ करोड
५६.४० करोड
५७.२२ करोड
EBITDA
२.२५ अरब
१.५५ अरब
२.१५ अरब
२.५१ अरब
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google एपहरू